Disruption of the Saccharomyces cerevisiae FAT1 Gene Decreases Very Long-chain Fatty Acyl-CoA Synthetase Activity and Elevates Intracellular Very Long-chain Fatty Acid Concentrations*

Paul A. WatkinsDagger §, Jyh-Feng Lu, Steven J. SteinbergDagger , Stephen J. Gouldparallel , Kirby D. Smith, and Lelita T. Braiterman

From the Kennedy Krieger Institute and Departments of Dagger  Neurology,  Pediatrics, and parallel  Biological Chemistry, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21205

    ABSTRACT
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Activation of fatty acids to their coenzyme A derivatives is necessary for subsequent metabolism. Very long-chain fatty acids, which accumulate in tissues of patients with X-linked adrenoleukodystrophy, are activated by very long-chain acyl-CoA synthetase (VLCS) normally found in peroxisomes and microsomes. We identified a candidate yeast VLCS gene (FAT1), previously identified as encoding a fatty acid transport protein, by its homology to rat liver peroxisomal VLCS. Disruption of this gene decreased, but did not abolish, cellular VLCS activity. Fractionation studies showed that VLCS activity, but not long-chain acyl-CoA synthetase activity, was reduced to about 40% of wild-type level in both 27,000 × g supernatant and pellet fractions. Separation of organelles in the pellet fraction by density gradient centrifugation revealed that VLCS activity was associated with peroxisomes and microsomes but not mitochondria. FAT1 deletion strains exhibited decreased growth on medium containing dextrose, oleic acid, and cerulenin, an inhibitor of fatty acid synthesis. FAT1 deletion strains grown on either dextrose or oleic acid medium accumulated very long-chain fatty acids. Compared with wild-type yeast, C22:0, C24:0, and C26:0 levels were increased approximately 20-, 18-, and 3-fold in deletion strains grown on dextrose, and 2-, 7-, and 5-fold in deletion strains grown on oleate. Long-chain fatty acid levels in wild-type and deletion strains were not significantly different. All biochemical defects in FAT1 deletion strains were restored to normal after functional complementation with the FAT1 gene. The level of VLCS activity measured in both wild-type and deletion yeast strains transformed with FAT1 cDNA paralleled the level of expression of the transgene. The extent of both the decrease in peroxisomal VLCS activity and the very long-chain fatty acid accumulation in the yeast FAT1 deletion model resembles that observed in cells from X-linked adrenoleukodystrophy patients. These studies suggest that the FAT1 gene product has VLCS activity that is essential for normal cellular very long-chain fatty acid homeostasis.

    INTRODUCTION
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Metabolism of fatty acids by either catabolic or anabolic pathways requires initial activation to their coenzyme A (CoA)1 thioesters, a reaction catalyzed by acyl-CoA synthetase (1). Differences in substrate chain length specificity and subcellular localization distinguish the various acyl-CoA synthetases present in cells from all species examined, including animals, yeast, bacteria, and plants (1). Long-chain fatty acids (C12-C20) are activated by long-chain acyl-CoA synthetases (LCSs) found in mitochondria, peroxisomes, and microsomes (1), reflecting the primary roles of these organelles in fatty acid beta -oxidation (mitochondria and peroxisomes) and complex lipid synthesis (microsomes). In contrast, activation of very long-chain fatty acids (VLCFA; C22 or longer) by very long-chain acyl-CoA synthetase (VLCS) takes place only in peroxisomal and microsomal subcellular fractions of rat (2), human (3), and yeast (4) cells. Lack of mitochondrial VLCS prevents this organelle from catabolizing VLCFA via beta -oxidation, thus relegating this function to the peroxisome.

VLCFA beta -oxidation is impaired in cells from patients with the progressive neurodegenerative disease X-linked adrenoleukodystrophy (XALD), resulting in elevated plasma and tissue concentrations of saturated VLCFA (5). Biochemical studies revealed that VLCS activity was decreased in peroxisomal, but not microsomal, subcellular fractions of fibroblasts from XALD patients (3, 6). However, further investigation of the molecular defect in XALD revealed that key steps in peroxisomal VLCFA metabolism are still poorly understood. The product of the gene defective in XALD (ALDP) is not VLCS, but rather is a peroxisomal membrane protein whose existence was previously unknown (7). Studies in many laboratories, including our own (8), clearly demonstrated that XALD patients have mutations in the ALD gene, and complementation studies confirmed that transfection of XALD cells with the ALD gene restores their ability to catabolize VLCFA (9, 10). While studies of XALD suggest that ALDP is required for VLCFA activation, the biochemical relationship between ALDP and VLCS has not yet been elucidated. Thus, to further our understanding of peroxisomal VLCFA activation, we are investigating this process in yeast.

Yeasts are unique model organisms for the study of peroxisomal fatty acid beta -oxidation, since they lack the mitochondrial beta -oxidation pathway found in higher animals. They have been valuable for identification of proteins subsequently shown to be defective in human disorders of peroxisome biogenesis (11-16). We previously reported that, as in mammalian tissues, peroxisomes and microsomes isolated from the yeast Pichia pastoris contain VLCS activity (4). The yeast Saccharomyces cerevisiae has been used by Gordon and co-workers to identify and characterize four fatty acid activation (FAA1-4) genes that encode acyl-CoA synthetases (17, 18). They examined the fatty acid substrate specificity of the protein products of three of these FAA genes (Faa1p, Faa2p, and Faa3p) in detail; while Faa3p weakly activated VLCFA, Faa1p and Faa2p had no detectable activity with these substrates (17). Faa4p was reported to be functionally interchangeable with Faa1p and thus is not likely to be a VLCS (18). Based on growth studies of yeast mutants in which all four FAA genes were disrupted, Gordon and colleagues concluded that at least one other FAA gene exists in S. cerevisiae (18).

Recently, Hashimoto and co-workers purified an enzyme with VLCS activity from rat liver peroxisomes (rVLCS) (19) and subsequently cloned and sequenced its cDNA (20). We identified an open reading frame on S. cerevisiae chromosome II (YBR041W; locus FAT1) with homology to the rVLCS amino acid sequence. Both rVLCS and the FAT1 gene product, Fat1p, are homologous to mouse fatty acid transport protein (mFATP), described by Schaffer and Lodish (21). Faergeman et al. (22) independently identified the FAT1 (fatty acid transporter 1) gene by virtue of the homology of Fat1p to mFATP. These investigators found that deletion of FAT1 resulted in decreased rates of cellular uptake of labeled long-chain fatty acid, decreased cellular uptake of fluorescent fatty acids, and decreased uptake and incorporation of labeled oleic acid into cellular phospholipids (22). Although they noted amino acid sequence similarities between Fat1p and acyl-CoA synthetases, these investigators found that deletion of the FAT1 gene did not affect LCS activity (22). However, they did not investigate either the role of Fat1p in VLCFA metabolism or the subcellular localization of this protein. In this report, we present evidence that Fat1p has VLCS activity and is present in both peroxisomes and a 27,000 × g supernatant fraction of S. cerevisiae. Furthermore, deletion of the FAT1 gene resulted in accumulation of VLCFA in yeast cells similar to that observed in plasma and tissues of XALD patients. These findings support the hypothesis that Fat1p is a VLCS whose activity is critical for normal cellular VLCFA homeostasis.

    EXPERIMENTAL PROCEDURES
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Identification of a Candidate S. Cerevisiae VLCS Gene-- Degenerate oligonucleotide primers (5'-GGYTCRTCYTTYTCNACRTC-3' and 5'-ACNGGNACNCCRTANACRTT-3') corresponding to two peptide fragments (referred to as internal sequences 1 and 2) of the rVLCS (19) were used to amplify by PCR a 348-base pair product using a liver cDNA library from a Gemfibrozil-treated rat as the template. Treatment of rats with the peroxisome proliferator Gemfibrozil was previously found to increase peroxisomal rVLCS activity by about 2-fold.2 The PCR product, containing an open reading frame with 45% amino acid identity to mFATP (21), was labeled with [32P]dCTP and used as a probe to screen the rat liver cDNA library. One clone (0.7 kb) containing an open reading frame of 220 amino acids was obtained; the nucleotide sequence of this clone was subsequently found to be identical to the carboxyl terminus of the rVLCS cDNA sequence later published (20). The 220-amino acid open reading frame was compared with all open reading frames of the complete S. cerevisiae genome (Saccharomyces Genome Data Base) using the BLAST algorithm (23). Only one likely candidate for a homologous yeast protein was identified (smallest sum probability = 9e-24). This gene (open reading frame YBR041W; locus FAT1) is found on chromosome II and is identical to that subsequently described by Faergeman et al. (22). The SWISS-PROT Data base entry for the protein (Fat1p) encoded by the FAT1 gene noted similarity to enzymes that act via an ATP-dependent covalent binding of AMP to their substrate.

Yeast Strains, Media, and Growth Conditions-- S. cerevisiae strain YPH680 (MATalpha his3Delta 200 leu2Delta 1 lys2Delta 202 trp1Delta 1 ura3-52) isogenic to YPH681 (MATa), a derivative of S288C (24), was the strain used for PCR-mediated disruption of the FAT1 gene. Cells were grown at 30 °C in rich medium containing dextrose as primary carbon source (YPD, consisting of 10 g/liter yeast extract (Life Technologies, Inc.), 20 g/liter Bacto-peptone (Difco), and 20 g/liter dextrose (Sigma)). For induction of peroxisomes, yeasts were grown in YPD to an A600 of 1. Cells were harvested by centrifugation at 3000 × g for 5 min, resuspended to an A600 of 0.5 in medium containing oleic acid as primary carbon source (YPOLT, where 0.2% (w/v) oleic acid (Sigma) solubilized with 0.02% (w/v) Tween 40 (Sigma) replaced dextrose), and grown for 12-14 h at 30 °C (25). Yeast growth characteristics were assessed on YPD/agar plates supplemented with 500 µM oleic acid and 0.033% (w/v) Tween 40, with or without 25 µM cerulenin (Sigma); 5 µl of cells diluted to an A600 of 0.01 were applied to plates and incubated for 16 h at 24 and 30 °C.

Cloning of FAT1 cDNA-- S. cerevisiae genomic DNA was isolated (26) and used as a template for PCR amplification of the FAT1 gene. PCR amplification was performed using the Expand Long Template PCR System (Boehringer Mannheim) with forward primer 5'-TACTGTCACCTTGATGAGCGAC-3' and reverse primer 5'-TCGATGGCTTCCCAATCAG-3'. Thirty-five cycles of 94 °C (20 s), 57 °C (60 s), and 68 °C (150 s) were performed. The resulting 2.2-kb amplicon containing the FAT1 gene (from -196 to +1990, where +1 is the first nucleotide of the translation initiation codon) was TA-cloned into pCR2.1 (Invitrogen) to produce pJFL3301. A HindIII/XbaI fragment from pJFL3301 was then cloned into the low copy number (CEN) vector pRS416 (27), producing pJFL3302. DNA sequencing of pJFL3302 was performed at the Johns Hopkins University Genetics Core Facility using the fluorescent dideoxy terminator method of cycle sequencing on an Applied Biosystems Inc. 373a automated DNA sequencer, following ABI protocols. Comparison of the sequence of pJFL3302 with that of FAT1 as contained in the Saccharomyces Genome Data base revealed that the data base sequence contained a CpC dinucleotide insertion at bp 1857-1858. Four subsequent attempts to amplify an 896-bp fragment containing this region using forward primer 5'-GGTGAAGGTTGCTTATGGTAACGG-3' and the reverse primer described above and PCR kits from three different manufacturers (Boehringer Mannheim, Promega, and Life Technologies, Inc.) yielded products with sequence identical to that contained in pJFL3302, ruling out random PCR-generated error. These findings suggested that the data base sequence may be in error. To verify this possibility, reverse transcription-PCR of wild-type yeast RNA was carried out as described below. RNA was treated with DNase I prior to cDNA synthesis. A 595-bp fragment of the FAT1 gene containing the putative CpC deletion region was amplified using the forward primer 5'-TTTCCTTGATAGAATGGGTG-3' and reverse primer 5'-CCTTTCCATATGTTATTAGG-3'. Sequencing of this fragment confirmed that the FAT1 transcript also lacked the CpC dinucleotide. Thus, we concluded that the data base sequence was in error, and this has been communicated to the curator of the Saccharomyces Genome Data base. Computer-assisted translation of our corrected FAT1 sequence yielded an open reading frame of 669 amino acids ending in -IKL, a yeast peroxisome targeting signal (28). The correct nucleotide sequence of FAT1 and the predicted amino acid sequence of Fat1p are shown in Fig. 1.

Computer-assisted translation of the coding sequence of pJFL3302 revealed that this plasmid encodes amino acids 1-662 of Fat1p plus 11 amino acids (EAEFQHTGGRY-COOH) derived from vector sequence. Since this construct did not contain the entire open reading frame of FAT1, we amplified by PCR a fragment containing the true 3'-end of the gene from genomic DNA. A 1-kb fragment was amplified using forward primer 5'-GGTGGAGGTTGCTTATGGTAACGG-3', reverse primer 5'-CCTTTCCATATGTTATTAGG-3', and Taq polymerase (Promega). Amplicons were TA-cloned into the pGEM-T Easy vector (Promega) to produce pJFL3305. A 223-bp Eco47III/SalI fragment of pJFL3305 was introduced into pJFL3302 to generate pJFL3307, which contains full-length FAT1 cDNA in the pRS416 (CEN) vector. The nucleotide sequence of pJFL3307 was correct with the exception of a silent mutation in amino acid Ser595. In complementation experiments, FAT1 deletion strains were transformed with pJFL3302 or pJFL3307 (26).

For overexpression studies, the complete FAT1 sequence was transferred to a high copy 2µ vector. A 2.2-kb Eco47III/ApaI fragment was transferred from pJFL3301 to pJFL3305 to form pJFL3306; the complete FAT1 open reading frame was excised from pJFL3306 with SpeI and XhoI and transferred to the 2µ vector pRS426 (27) to form pSJW981. Here, we refer to the sequence contained in pJFL3302 as FAT1-1 and that contained in pJFL3307 and pSJW981 as FAT1.

Construction of FAT1 Gene Deletion Strains-- PCR-mediated gene disruption of the FAT1 gene was performed by the method of Lorenz et al. (29). A forward primer consisting of 40 nucleotides of FAT1 sequence upstream of the initiation ATG and 20 left primer sequence-specific nucleotides for pRS plasmids (5'-TCTATATCGTTGAACTTTTAATAGGCTGCGAATACCGACTCTGTGCGGTATTTCACACCG-3') and a reverse primer consisting of 40 nucleotides of FAT1 sequence downstream of the stop codon (as contained in the Saccharomyces Genome Data base; nucleotides 1871-1910) plus 20 right primer sequence-specific nucleotides for pRS plasmids (5'-TCCAAACCCTTTGGTAATTTTTGCTCTCTATAAACCTTCTAGATTGTACTGAGAGTGCAC-3') were used to amplify pRS303 using a two-step program (24). Seven HIS prototrophs were selected following transformation of YPH680 with this PCR product (26). PCR using the forward and reverse primers used to clone FAT1 (described above) and genomic DNA prepared from wild-type and candidate gene disruption strains was performed to confirm disruption of FAT1. PCR products were separated by electrophoresis on 1% agarose gels. Four of the seven strains contained a PCR product of the expected size (1231 bp) for FAT1 disruption. The expected 2186-bp PCR product was observed in wild-type strains.

Induction of Peroxisomes and Subcellular Fractionation of Yeast-- Peroxisomes were induced in wild-type and gene deletion yeast strains by growth in YPOLT medium as described above. Spheroplasts were prepared, homogenized, and fractionated into 27,000 × g supernatant and organelle pellet as described by Crane et al. (25). In some experiments, the organelle pellet was further fractionated by centrifugation on linear Nycodenz (sold as Accudenz by Accurate Chemical and Scientific) gradients (30). 0.5 ml of Maxidens (sold as Purdenz by Accurate Chemical and Scientific) was placed at the bottom of a 13-ml Beckman Quickseal tube, followed by a 10.5-ml linear gradient of 15% Nycodenz and 0.25 M sucrose (top) to 42.5% Nycodenz and 0.125 M sucrose (bottom) in 5 mM MES, pH 6.0, 1 mM EDTA, 1 mM KCl, 0.1% ethanol. The organelle pellet in homogenization buffer (5 mM MES, pH 6.0, 0.6 M sorbitol, 0.5 mM EDTA, 1 mM KCl, 0.1% ethanol) was layered on top of the Nycodenz, and tubes were centrifuged for 75 min at 174,000 × g in a vertical ultracentrifuge rotor. Fractions of 0.5 ml were collected from the bottom of the tube and assayed for acyl-CoA synthetase activity (below) and marker enzyme activity as described previously (4). Because protein cannot be quantitated accurately in Nycodenz solutions, and because this compound had been shown to inhibit other fatty acid metabolic pathways (31), in some experiments, peak peroxisomal and mitochondrial fractions were pooled and dialyzed against 10 mM MES, pH 7.0, prior to assay.

Assay of Acyl-CoA Synthetase Activity-- Acyl-CoA synthetase activity was measured essentially as described previously (32). Labeled fatty acids, [1-14C]lignoceric acid (C24:0; American Radiolabeled Chemicals) and [1-14C]palmitic acid (C16:0; NEN Life Science Products) were solubilized in alpha -cyclodextrin (Sigma) and incubated with enzyme for 20 min at 30 °C in 40 mM Tris-Cl, pH 7.5, containing 10 mM ATP, 5 mM MgCl2, 0.2 mM CoA, and 0.2 mM dithiothreitol. Labeled acyl-CoAs were extracted from the reaction mixture by the method of Dole (33) and quantitated in a Beckman LS 3801 liquid scintillation counter. Protein was determined by the method of Lowry et al. (34).

Reverse Transcription-PCR of FAT1 cDNA-- Total RNA was isolated from spheroplasts prepared from yeast, grown in either YPD or YPOLT medium, using an RNeasy kit (Qiagen). cDNA synthesis was from 1.0 µg of RNA (pretreated with DNase I; Boehringer Mannheim) from yeast grown under each condition and utilized 20 ng of (dT)15 (Boehringer Mannheim) and 100 ng of hexanucleotides (Sigma) as primers. The reaction was carried out at 42 °C for 1 h with 20 units of Moloney murine leukemia virus reverse transcriptase (Boehringer Mannheim), buffer supplied with the enzyme, 20 units of RNasin (Promega), and 125 µM each dNTP. After treatment at 95 °C for 3 min, an equal aliquot of each reverse transcription reaction was used as PCR template with forward primer 5'-TTTCCTTGATAGAATGGGTG-3' and reverse primer 5'-CCAATCAGCAGCGGTCAAGA-3' designed to amplify a 424-bp fragment of FAT1 cDNA. An additional PCR was carried out using forward primer 5'-CCCAGATCTATGAGCAGTCGTGTGTGCTAC-3' and reverse primer 5'-CCCGAGCTCAGTTGTGAAGCACTTTAGTTAC-3' (kindly provided by Dr. M. Geraghty) designed to amplify a 1116-bp fragment containing YOR180C (locus EDH2), a peroxisomal enoyl-CoA hydratase gene with a consensus upstream oleate response element. Thirty-five cycles of 94 °C (45 s), 55 °C (45 s), and 72 °C (60 s) were performed using the Expand High Fidelity PCR system (Boehringer Mannheim).

Fatty Acid Analysis-- Yeast grown in either YPD (250 A600) or YPOLT (60 A600) were harvested by centrifugation, washed three times with deionized water, suspended in 0.5 ml water, and subjected to sonic disruption. After determination of the protein concentration by the method of Miller (35), total lipids were extracted by a modification of the method of Folch et al. (36), and total fatty acids were quantitated by gas chromatography as their methyl esters using the method of Moser and Moser (37).

    RESULTS
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Identification of FAT1 as a Candidate S. cerevisiae VLCS Gene-- A cDNA library from the liver of a rat treated with the peroxisome proliferator Gemfibrozil was screened, and a 660-bp fragment containing a 220-amino acid open reading frame thought to be the carboxyl terminus of rat VLCS was cloned as described under "Experimental Procedures." The sequence of this fragment was 100% identical to that of authentic rat liver VLCS, which was subsequently published by Uchiyama et al. (20). The 220-amino acid sequence was compared with all open reading frames of the complete S. cerevisiae genome using the BLAST algorithm. Only one likely candidate for a homologous yeast protein was identified (smallest sum probability = 9e-24). The gene encoding this protein was identical to that recently reported by Faergeman et al. (22), which they designated FAT1 by virtue of its homology to mFATP.

While preparing expression constructs to investigate the biochemical properties of Fat1p, the product of the FAT1 gene, we detected an error in the sequence as contained in the Saccharomyces Genome Data Base. The published sequence contained a CpC dinucleotide insertion at bp 1857 and 1858, yielding an open reading frame of 623 amino acids. The corrected nucleotide sequence of FAT1 and its predicted amino acid sequences are shown in Fig. 1. The FAT1 gene encodes a protein of 669 amino acids with 33.7% identity and 57.2% similarity to rVLCS. Although the signal that targets rVLCS to peroxisomes is not certain, the protein ends in the carboxyl-terminal tripeptide -LKL (20) and may be a functional variant of the well characterized -SKL peroxisome targeting signal 1 (38). Fat1p ends in the carboxyl-terminal tripeptide -IKL, which has been shown to function as a peroxisome targeting signal 1 in yeast (28). To investigate the function of Fat1p, PCR-mediated gene disruption was used to replace the FAT1 gene with the HIS selectable marker as described under "Experimental Procedures."


View larger version (69K):
[in this window]
[in a new window]
 
Fig. 1.   Corrected nucleotide sequence of FAT1 and its deduced amino acid sequence. The coding region of FAT1 as contained in the Saccharomyces Genome Data base was found to have a CpC insertion at bp 1857 and 1858. Removal of this dinucleotide changed the open reading frame beginning at amino acid 620 from -LIKFstop to that shown here. The open reading frame of the corrected sequence contains 669 amino acids. Nucleotides are numbered on the left and amino acids on the right.

VLCS and LCS Activity of FAT1 Deletion Strains-- In order to identify mutants in which the FAT1 gene had been disrupted and to ascertain whether Fat1p had VLCS activity, seven HIS prototrophs were assayed for their ability to activate a VLCFA, lignoceric acid (C24:0), to its CoA derivative. Spheroplasts were prepared from wild-type yeast and these candidate FAA1 deletion strains. Spheroplast homogenates from four strains in which FAA1 gene disruption was confirmed by PCR (see "Experimental Procedures") also had decreased ability to activate lignoceric acid, suggesting that Fat1p has VLCS activity that was indeed disrupted. In these strains, LCS activity was similar to that of wild-type. Data from the two strains chosen for further study, designated fat1Delta -1 and fat1Delta -2, are shown in Table I.

                              
View this table:
[in this window]
[in a new window]
 
Table I
Acyl-CoA synthetase activities in homogenates of wild-type and FAT1 deletion S. cerevisiae strains
Wild-type (wt) S. cerevisiae and FAT1 deletion strains (fat1Delta -1 and fat1Delta -2) were homogenized with glass beads, and acyl-CoA synthetase activity of homogenates was measured as described under "Experimental Procedures" using either a long-chain fatty acid (palmitic acid; C16:0) or a very long-chain fatty acid (lignoceric acid; C24:0) as substrate.

The acyl-CoA synthetase activity of wild-type S. cerevisiae assayed using a VLCFA substrate, lignoceric acid, was more than 100-fold less than that measured using a long-chain fatty acid, palmitate (C16:0) (Table I), in agreement with our previous observations in the yeast Pichia pastoris (4). In the FAT1 deletion strains, VLCS activity was reduced to <30% of wild-type level. Residual VLCS activity in deletion strains was clearly detectable; radioactivity in VLCS assays of these strains was >= 2-fold higher than in enzyme-free control reactions. In contrast, LCS activity of FAT1 deletion strains was relatively unaffected (Table I). These findings indicate that Fat1p is responsible for activation of a considerable fraction of cellular VLCFAs; however, it appears that Fat1p is not the only enzyme with VLCS activity.

Growth of FAT1 Deletion Strains on Fatty Acids-- Growth of wild-type, FAT1 deletion, and FAT1 deletion complemented with FAT1 cDNA strains on YPD plates supplemented with 500 µM oleic acid was comparable at both 24 and 30 °C; in contrast, growth of the FAT1 deletion strain was markedly reduced at 24 °C and somewhat reduced at 30 °C when cerulenin, an inhibitor of fatty acid synthase (39), was added to the oleic acid growth medium (data not shown). This growth phenotype is similar to that reported previously for FAT1 deletion mutants (22). Transformation of FAT1 deletion strains with FAT1 cDNA restored growth to normal (data not shown).

FAT1 Gene Deletion Strains Accumulate VLCFAs-- In XALD and in peroxisome biogenesis disorders, failure of peroxisomes to activate VLCFAs results in their accumulation in tissues (5). To determine whether deletion of the FAT1 gene affected VLCFA accumulation in yeast, fatty acid analysis was performed on wild-type, fat1Delta -1, and fat1Delta -2 strains grown in both YPD medium and in YPOLT medium to induce peroxisomes. As shown in Fig. 2, the cellular concentration of saturated fatty acids with chain lengths greater than or equal to C22 was increased in FAT1 deletion strains grown on YPD. The concentrations of saturated fatty acids containing 14-20 carbons were similar in both wild-type and deletion strains (data not shown). When wild-type yeasts were grown on YPOLT instead of YPD, concentrations of saturated fatty acids, both VLCFA (Fig. 2) and long-chain fatty acids (data not shown), were 5-10-fold higher. As in YPD-grown yeast, FAT1 deletion strains grown on YPOLT had increased concentrations of VLCFA, particularly C24:0 and C26:0 (Fig. 2), relative to wild-type yeast grown under the same conditions. Long-chain fatty acid concentrations were similar in YPOLT-grown wild-type and FAT1 deletion strains.


View larger version (14K):
[in this window]
[in a new window]
 
Fig. 2.   Cellular fatty acid concentrations in YPD- and YPOLT-grown wild-type and FAT1 deletion strains. Yeasts were either grown in YPD medium black-square or grown under conditions for induction of peroxisomes as described under "Experimental Procedures" (square ; YPOLT medium). Total fatty acids were extracted and quantitated as their methyl esters as described under "Experimental Procedures." Concentrations of the VLCFAs C22:0, C24:0, and C26:0 are expressed as µg of fatty acid per mg of cellular protein.

To verify that elevations in VLCFA concentrations were specific and not the result of an overall increase in fatty acids in these cells, we calculated the cellular content of these fatty acids as a percentage of total fatty acids. As shown in Fig. 3, the increase in cellular content of VLCFA in FAT1 deletion strains was similar to the increase in cellular concentration of VLCFA (Fig. 2) in both YPD- and YPOLT-grown yeast. YPD-grown deletion strains preferentially accumulated behenic acid (C22:0) and lignoceric acid (C24:0), which were 20- and 18-fold higher in fat1Delta -1 and fat1Delta -2 strains than in the wild-type strain. YPOLT-induced deletion strains, on the other hand, mainly accumulated lignoceric acid and hexacosanoic acid (C26:0), which were 7- and 5-fold higher than in wild-type. To verify that the elevation in VLCFA content of FAT1 deletion strains was due solely to the lack of Fat1p, we transformed FAT1-1 cDNA (pJFL3302) into the fat1Delta -1 and fat1Delta -2 strains. Wild-type and deletion strains were also transformed with the vector alone. After growth on YPOLT, the cellular content of saturated VLCFA was determined. As shown in Fig. 4, C22:0, C24:0, and C26:0 were all restored to wild-type levels in deletion strains transformed with FAT1-1 cDNA. When deletion strains were transformed with FAT1 cDNA (pJFL3307), similar results were obtained (data not shown). These results strongly suggest that Fat1p is required for utilization of VLCFAs in S. cerevisiae and that this protein plays a significant role in regulating VLCFA metabolism.


View larger version (24K):
[in this window]
[in a new window]
 
Fig. 3.   Fatty acid analysis of wild type (WT) and FAT1 deletion yeast strains. Yeast were grown on either YPD (A) or YPOLT (B) as in Fig. 2. Total fatty acids were extracted and quantitated as their methyl esters as described under "Experimental Procedures." The abundance of each fatty acid was calculated as a percentage of total cellular fatty acids. For wild-type yeast grown on YPD, values for even numbered saturated fatty acids from C14:0 to C26:0 were 0.62, 19.5, 6.15, 0.50, 0.078, 0.098, and 0.37% of total fatty acids, respectively. Corresponding values for wild-type yeast grown on YPOLT were 0.16, 4.14, 1.18, 0.17, 0.024, 0.032, and 0.045%, respectively. Results are expressed as a percentage of wild-type fatty acid content. Gray bar, wild type; filled bar, fat1Delta -1; open bar, fat1Delta -2.


View larger version (29K):
[in this window]
[in a new window]
 
Fig. 4.   FAT1-1 cDNA restores cellular VLCFA content to wild-type (WT) levels in FAT1 deletion strains. Wild-type and deletion strains were transformed with either the CEN vector alone (pRS416) or the vector containing FAT1-1 cDNA (pJFL3302). After growth on YPOLT medium, fatty acids were analyzed as in Fig. 2. The content of each fatty acid was calculated as a percentage of total cellular fatty acids. For wild-type yeast transformed with vector alone, the content of C22:0, C24:0, and C26:0 was 0.046, 0.076, and 0.091%, respectively. Results are expressed as a percentage of wild-type fatty acid content. , wild type plus vector; black-square, fat1Delta -1 plus vector; , fat1Delta -1 plus pJFL3302; , fat1Delta -2 plus vector; , fat1Delta -2 plus pJFL3302.

VLCS Activity of Both Organelle Pellet and Supernatant Fractions Is Reduced upon Deletion of FAT1 and Is Restored by Expression of FAT1 cDNA-- We previously demonstrated that in the yeast P. pastoris, VLCS activity was present in both 27,000 × g microsome-rich supernatant and organellar pellet fractions (4). When homogenates of S. cerevisiae spheroplasts were subjected to the same procedure, VLCS activity was also found in both the peroxisome- and mitochondria-rich organelle pellet and the cytosol- and microsome-rich supernatant (Table II). As expected, these fractions also exhibited high LCS activity. In wild-type yeast, the organelle pellet fraction contained about 60% of the total cellular LCS activity and about 30% of the total VLCS activity (data not shown). To determine whether Fat1p was responsible for VLCFA activation in supernatant, organelle pellet, or both, fat1Delta -1 and fat1Delta -2 strains were also fractionated. In these deletion strains, the specific activity of VLCS was decreased in both the organelle pellet and the supernatant fractions. The relative decrease was greater in the microsome-rich supernatant than in the organelle pellet. The LCS activity of the fat1Delta -1 strain was more variable and slightly lower than in either the wild-type or the fat1Delta -2 strain; the cause of this variability is unknown.

                              
View this table:
[in this window]
[in a new window]
 
Table II
Acyl-CoA synthetase activity in organelle pellet and supernatant fractions of wild-type and FAT1 deletion strains
Spheroplasts were prepared from oleate-grown wild-type (wt) and FAT1 deletion yeast strains, homogenized, and fractionated into an organelle pellet and a 27,000 × g supernatant as described under "Experimental Procedures." Acyl-CoA synthetase activity with either C16:0 or C24:0 as substrate was measured as described under "Experimental Procedures." Data are presented as mean ± S.D. of specific activities for the number of experiments indicated in parentheses.

To verify that the decrease in VLCS activity in the FAT1 deletion strains was caused by lack of Fat1p, we assayed fractions prepared from wild-type, fat1Delta -1, and fat1Delta -2 strains that were transformed with either FAT1-1 cDNA (pJFL3302) or the vector alone. As shown in Table III, expression of FAT1-1 cDNA (on the low copy number CEN vector) in the wild-type strain resulted in a slight increase in VLCS activity in the organelle pellet. In deletion strains expressing Fat1p, VLCS activity in the organelle pellet was similar to the activity in this fraction from vector-transformed wild-type (Table III). VLCS activity of supernatant fractions from deletion strains transformed with FAT1-1 cDNA was restored to about 75% of wild-type activity (Table III).

                              
View this table:
[in this window]
[in a new window]
 
Table III
Restoration of VLCS activity in FAT1 deletion strains by functional complementation with FAT1-1 cDNA
Wild-type (wt) or FAT1-deletion yeast strains were transformed with either the CEN vector pRS416 or the vector containing FAT1-1 cDNA (pJFL3302) as described under "Experimental Procedures." Spheroplasts were prepared and fractionated into an organelle pellet and 27,000 × g supernatant as described under "Experimental Procedures" prior to an assay of acyl-CoA synthetase activity with the indicated substrate. The average of two independent transformation experiments is presented.

Overexpression of VLCS Activity in Wild-type and FAT1 Deletion Strains-- To verify that Fat1p catalyzes VLCS activity, we overexpressed FAT1 cDNA in yeast strains. pSJW981, a high copy plasmid containing FAT1 cDNA, was transformed into both the wild-type and fat1Delta -2 strains. As shown in Fig. 5, a 4-fold increase over wild-type VLCS activity was observed in the wild-type strain transformed with pSJW981. The VLCS activity of the pSJW981-transformed deletion strain was nearly 3-fold higher than wild-type level (Fig. 5). Comparison of the VLCS activities of both the wild-type strain and fat1Delta -2 strain transfected with the low copy CEN plasmid (Table III) versus the high copy 2µ construct (Fig. 5) showed a correlation between level of VLCS activity and the level of expression of the transgene. These results indicate that Fat1p indeed catalyzes VLCS activity.


View larger version (38K):
[in this window]
[in a new window]
 
Fig. 5.   Overexpression of Fat1p produces higher than normal VLCS activity in wild-type (WT) and FAT1 deletion strains. Wild-type and the fat1Delta -2 deletion strains were transformed with the high copy 2µ plasmid containing FAT1 cDNA (pSJW981). Spheroplasts were prepared from native and transformed strains, homogenized, centrifuged for 5 min at 2500 × g to remove nuclei and unbroken cells, and assayed for VLCS activity as described under "Experimental Procedures." Results are presented as a percentage of wild-type VLCS activity and are the average of two independent experiments.

VLCS Is Not Induced by Peroxisome Proliferation-- Treatment of rats with peroxisome proliferators such as Gemfibrozil was found to increase the specific activity of peroxisomal VLCS.2 In yeast, peroxisome proliferation and the synthesis of several peroxisomal beta -oxidation enzymes are induced by growth on medium containing a fatty acid such as oleic acid as primary carbon source (40, 41). A 21-24-bp oleate response element has been identified in the 5'-untranslated region of the genes encoding these proteins; however, Faergeman et al. (22) reported that there was no consensus oleate response element in the 5'-untranslated region of the FAT1 locus. We wanted to ascertain directly whether oleate-induced peroxisome proliferation in S. cerevisiae would increase VLCS activity and the level of FAT1 mRNA. When wild-type yeast were grown in oleic acid-containing medium, we did not observe an increase in VLCS activity over that of dextrose-grown yeast (data not shown). To estimate relative FAT1 mRNA levels, total RNA was isolated from spheroplasts prepared from yeast grown in either medium. When equal amounts of RNA were used for reverse transcriptase-catalyzed cDNA synthesis, no increase in FAT1 message in oleate-grown cells was detected by PCR (Fig. 6), consistent with the lack of an upstream oleate response element. In contrast, there was a marked increase in mRNA for EDH2, a gene encoding a peroxisomal enoyl-CoA hydratase that contains an oleate response element (Fig. 6).


View larger version (80K):
[in this window]
[in a new window]
 
Fig. 6.   FAT1 is not induced by growth on oleic acid. Wild-type yeasts were grown either on YPD (lanes B and D), or on YPOLT to induce peroxisomes (lanes C and E). Total RNA was isolated, and reverse-transcription of an equal amount of RNA was performed as described under "Experimental Procedures." PCR was carried out using primers designed to amplify a 424-bp fragment of FAT1 (lanes A and B; lower arrow) or a 1116-bp fragment of EDH2, a gene containing an oleate response element (lanes D and E; upper arrow). PCR products were separated on a 1.5% agarose gel. DNA size markers (1-kb ladder) are in lane A.

VLCS Activity of Fat1p in the Organelle Pellet Fraction Is Peroxisomal-- Because peroxisome induction by oleate in wild-type yeast failed to increase either FAT1 message (Fig. 6) or VLCS activity (data not shown), we questioned whether the VLCS activity in the organelle pellet was associated with peroxisomes or mitochondria. Although fatty acid beta -oxidation does not take place in mitochondria, VLCFA activation for complex lipid synthesis or elongation could take place in this organelle. To address this question, we fractionated the organelle pellet from wild-type and gene deletion strains by density gradient centrifugation. As shown in Fig. 7, C and D, peroxisomes and mitochondria were well separated in both wild-type and FAT1 deletion strains. VLCS activity was associated mainly with peroxisomal gradient fractions, with a small amount of activity found in a low density fraction near the top of gradients (Fig. 7B). Mitochondrial fractions had very little VLCS activity. In contrast, LCS activity was present in mitochondrial, peroxisomal, and low density fractions (Fig. 7A). It is likely that this low density fraction contains both enzyme released from peroxisomes during processing and heavier microsomes that sedimented at 27,000 × g. Using this fractionation procedure, VLCS activity in both peroxisomal and low density fractions of the FAT1 deletion strains was found to be decreased (Fig. 7B).


View larger version (32K):
[in this window]
[in a new window]
 
Fig. 7.   Isolation of peroxisomes from wild-type and FAT1 deletion strains by density gradient centrifugation. Wild-type yeast and the fat1Delta -1 strain were grown on YPOLT medium to induce peroxisomes. Peroxisome-containing organelle pellets prepared from an equal A600 of each strain were subjected to Nycodenz density gradient centrifugation as described under "Experimental Procedures." Fractions of 0.5 ml were collected from the bottom of the tube and assayed for activation of C16:0 (A) and C24:0 (B). Marker enzyme activities in wild-type (C) and fat1Delta -1 (D) yeast were also measured to localize peroxisomes (catalase; light bars) and mitochondria (succinate dehydrogenase; dark bars). This experiment was performed three times with similar results.

To verify that the observed difference in activity between gradient fractions from wild-type and gene deletion strains was not the result of differential loading of gradients, peak fractions corresponding to peroxisomes, mitochondria, and low density organelles were pooled and dialyzed, and specific activities were determined. As shown in Table IV, specific VLCS activity in peroxisomes was decreased in the fat1Delta -1 strain. Peroxisomal LCS specific activity was also decreased in this strain. The LCS activity in the organelle pellet fraction of the fat1Delta -1 strain was in general somewhat lower than that of wild-type (Table II); the significance of this result is currently under investigation. The low density fraction from the deletion strain also had decreased VLCS specific activity. VLCS activity in the mitochondrial fraction was very low, only 10% of that in the peroxisomal fraction, and was not appreciably decreased in the gene deletion strain. Overall, our results indicate that VLCS activity in S. cerevisiae appears to be catalyzed, at least in part, by Fat1p.

                              
View this table:
[in this window]
[in a new window]
 
Table IV
Acyl-CoA synthetase activity of peroxisomal, mitochondrial, and low density fractions of wild-type and FAT1 deletion organelle pellets
Organelle pellets prepared from either wild-type (wt) or fat1Delta -1 strains were fractionated on continuous Nycodenz gradients as described under "Experimental Procedures" and in Fig. 7. Fractions containing peak activities of the peroxisomal marker enzyme catalase and the mitochondrial marker enzyme succinate dehydrogenase, as well as the two lowest density fractions, were pooled and dialyzed for 3 h at 4 °C against 10 mM MES, pH 7.0, to remove Nycodenz prior to an assay of acyl-CoA synthetase activity with either C16:0 or C24:0 as substrate. Specific activities of pooled fractions are the average of two independent gradient fractionations.

    DISCUSSION
Top
Abstract
Introduction
Procedures
Results
Discussion
References

In this report, we provide evidence that the S. cerevisiae FAT1 gene product, Fat1p, has VLCS activity. While several yeast enzymes with acyl-CoA synthetase have been reported, Fat1p is the first described that appears to play a significant role in VLCFA metabolism. Four yeast acyl-CoA synthetases were previously described by Gordon and colleagues (17, 18). These investigators also predicted the existence of at least one additional fatty acid activation gene that directs fatty acids to the beta -oxidation pathway after they found that strains in which all four FAA genes were disrupted were viable on media containing fatty acids as sole carbon source (18). Faa1p, Faa2p, and Faa4p were very active toward medium- to long-chain fatty acids but showed no VLCS activity. Faa3p, expressed in bacteria as a His6 fusion protein, weakly activated fatty acids over a broad range of chain lengths from 12 to 24 carbons. Although Faa3p was the only one of this group that demonstrated any activity toward VLCFAs, the activity of the recombinant enzyme with fatty acids of all chain lengths was very low. Studies to determine whether Faa3p or any of the other known yeast acyl-CoA synthetases are responsible for the residual VLCS activity in FAT1 deletion strains are in progress.

Deletion of the FAT1 gene resulted in decreased growth on rich medium containing both dextrose and oleic acid when an inhibitor of fatty acid synthesis, cerulenin, was present. This result is in agreement with findings reported by Faergeman et al. (22), who independently identified the FAT1 gene by virtue of the homology of Fat1p to mFATP, a mouse protein thought to be involved in fatty acid transport (21). In their study, FAT1 deletion strains showed evidence of defective fatty acid uptake into cells and decreased incorporation of labeled oleic acid into cellular phospholipids (22). However, when we quantitated total fatty acids in yeast grown on either dextrose- or oleate-containing medium, no difference in the concentrations of C14:0, C16:0, or C18:0 were found in wild-type, fat1Delta -1, and fat1Delta -2 strains (Fig. 3). FAT1 gene deletion caused yeast to accumulate VLCFA when grown on either dextrose or oleic acid as primary carbon source, suggesting that the primary role of Fat1p is in VLCFA metabolism. Furthermore, it is possible that the biochemical effects in deletion mutants ascribed to defects in fatty acid transport result from perturbation of the cell membrane lipid composition by increased VLCFA concentrations. Alterations in membrane properties by VLCFAs have been described in model membranes (42), erythrocyte membranes (43), and adrenocortical cell membranes (44).

Our results clearly indicate that FAT1 deletion strains are unable to effectively utilize VLCFA. Accumulation of VLCFA could result from overproduction, failure to incorporate these fatty acids into complex lipids, failure to degrade excess fatty acids by peroxisomal beta -oxidation, or a combination of these processes. When yeast are grown on rich medium containing oleate, the cellular long-chain fatty acid content is 5-10-fold higher than when cells are grown on dextrose medium (data not shown), and VLCFA would be expected to arise primarily from chain elongation. However, when cells are grown in dextrose medium, fatty acids (including VLCFA) for biosynthesis of complex lipids could originate either from de novo synthesis or from lipids present in the yeast extract component of the medium. In either case, failure to activate VLCFA, either for incorporation into complex lipids or for degradation via beta -oxidation, could result in significant accumulation within yeast cells. Furthermore, if Fat1p, in addition to its role in VLCFA activation also functions to transport VLCFA across organellar membranes, lack of this protein could similarly result in cellular accumulation of VLCFA.

Because of the association of defective peroxisomal fatty acid metabolism with human neurodegenerative diseases, we wanted to verify that yeast Fat1p was an acyl-CoA synthetase and to determine its subcellular location. Faergeman et al. (22) reported that deletion of the FAT1 gene did not decrease acyl-CoA synthetase activity in sonicated cell extracts when myristate (C14:0), palmitate (C16:0), or oleate (C18:1) was supplied as substrate. Similarly, we found no decrease in LCS activity in yeast spheroplast homogenates using palmitate as substrate (Table I). In contrast, total yeast VLCS activity as well as that of peroxisomes and a microsome-rich 27,000 × g supernatant fraction was significantly decreased when the FAT1 gene was deleted, indicating that Fat1p has VLCS activity (Tables I and II). The only other yeast acyl-CoA synthetase whose subcellular distribution has been studied is Faa2p, which was found to be almost exclusively associated with peroxisomes (45). Faa2p, which had no VLCS activity, was found to be most active toward medium chain length saturated fatty acids (C10:0-C14:0) (17). The subcellular distribution of Faa1p, Faa3p, and Faa4p is unknown.

Decreased peroxisomal VLCS activity and elevated cellular VLCFA levels are consistent biochemical features of XALD. As reported here, deletion of the gene encoding the only S. cerevisiae protein that shares significant homology with mammalian VLCS produces a similar biochemical phenotype. However, the gene defective in XALD encodes ALDP, a protein of the ATP-binding cassette membrane transporter superfamily, and not VLCS (7). ALDP and at least three other structurally related proteins of this family are found in mammalian peroxisomal membranes (46-48). Yeasts contain only two peroxisomal proteins belonging to this family, Pxa1p (49) and Pxa2p (50) (also known as Pat2p and Pat1p, respectively (45)), which have been proposed as functional homologs of ALDP. Deletion of either the PXA1 or PXA2 genes resulted in decreased growth on medium containing oleate as primary carbon source (45, 49, 50), whereas no growth phenotype of FAT1 deletion strains was evident under the same conditions. Shani et al. (50) found that Pxa1p and Pxa2p function as a heterodimer. Hettema et al. (45) concluded that these two yeast ATP-binding cassette transporter proteins functioned to transport long-chain fatty acyl-CoAs into peroxisomes for catabolism via beta -oxidation. Furthermore, they concluded that the acyl-CoAs transported by these proteins were activated by acyl-CoA synthetases located on organelles other than peroxisomes. They further concluded that Pxa1p and Pxa2p were not required for transport into peroxisomes of medium chain free fatty acids, which were subsequently activated inside the peroxisome by Faa2p. Preliminary data indicate that, in contrast to deletion of FAT1, deletion of PXA1 or PXA2 did not increase cellular C22:0 or C24:0 concentrations significantly.3 Thus, it appears that the functional relationship between VLCS and ATP-binding cassette transporters may differ between yeasts and humans and introduces the possibility that Fat1p both activates and transports peroxisomal VLCFAs. Further studies to probe the relationship among Fat1p, Pxa1p, and Pxa2p and to determine whether Fat1p also functions as a peroxisomal transporter are currently in progress.

VLCSs and mFATP appear to belong to the same protein family. rVLCS shares 40% amino acid identity and 73% similarity with mFATP (20). Faergeman et al. (22) noted that Fat1p and mFATP contain several regions of high sequence similarity, including a consensus sequence (amino acids 255-268 of Fat1p; see Fig. 8, Motif 1) common to all known acyl-CoA synthetases and other proteins (e.g. insect luciferases and plant coumarate CoA ligase) with an AMP-binding domain (51). Another region of sequence similarity between Fat1p and mFATP contains a motif (amino acids 519-540 of Fat1p; Fig. 8, Motif 2) that is highly conserved between these proteins, rat peroxisomal VLCS (20), and human VLCS4 (52). When the comparable regions of rat and human LCSs and yeast Faa1p-4p are aligned, it is clear that proteins in this group are more closely related to each other than to the VLCS/FATP group. An acyl-CoA synthetase "signature motif" described by Black et al. (53) (consisting of eight invariant amino acid residues in a 25-amino acid consensus sequence) is partially contained in motif 2; residues 19-25 of the signature motif are residues 1-7 of motif 2. Conserved residues 4 and 5 of motif 2 (DR) are invariant amino acids of the signature motif. However, only amino acids 1, 7, and 8 (DXXXXXGD) of the signature motif were also present in rVLCS, a protein known to possess acyl-CoA synthetase activity, indicating that the signature motif may require only five invariant residues. Notably, the DXXXXXGD sequence was also present in all enzymes of the VLCS/FATP group (data not shown), suggesting that all of these proteins could have acyl-CoA synthetase activity.


View larger version (24K):
[in this window]
[in a new window]
 
Fig. 8.   Conserved motifs in acyl-CoA synthetases. Two homologous regions (motif 1 and motif 2) of yeast Fat1p, mFATP, and 11 long-chain and very long-chain acyl-CoA synthetases were aligned. Motif 1 is a 10-amino acid sequence starting at position 255 of Fat1p, and motif 2 is a 22- or 23-amino acid sequence beginning at position 519. VCLS sequences were from rat, mouse, and human proteins (rVLCS, mVLCS, and hVLCS). LCS sequences were from rat (rACS-1, -2, and -3), human (hACS), and yeast (Faa1p-4p). Sources of sequences are indicated on the right. *, S. Kemp, personal communication. **, S. J. Steinberg and P. A. Watkins, submitted for publication.

Yeasts have proven to be extremely valuable in the study of peroxisomes and peroxisomal lipid metabolism. This organism has been extensively used to identify and characterize many proteins required for peroxisome biogenesis; indeed, protein defects in 6 of the 11 recognized complementation groups of human peroxisome biogenesis disorders were elucidated by virtue of their homology to proteins first identified in yeast (11-16). In this study, we have demonstrated that deletion of the FAT1 gene results in VLCFA accumulation, a cellular phenotype resembling that found in XALD. The finding that VLCS activity was not totally abolished in FAT1 gene deletion strains suggests that a known (Faa1p-4p) or unknown acyl-CoA synthetase is responsible for the residual activity. This conclusion is in concert with the observation that in XALD, peroxisomal beta -oxidation of VLCFA is reduced (20-30% of control) but not decreased to the same extent as seen in the disorders of peroxisome biogenesis (<10% of control) (54). The nature of the enzyme(s) responsible for residual VLCS activity in yeast and the elucidation of similar enzyme(s) in humans are the subject of current investigation.

    ACKNOWLEDGEMENTS

We thank Ann Moser for assistance with fatty acid analysis, Susan J. Wang for expert technical assistance, Dr. Michael Geraghty for primers for PCR amplification of YOR180C, Drs. Noam Shani and David Valle for sharing their data on fatty acid levels in PXA1 and PXA2 deletion yeast strains prior to publication, Stephan Kemp for the amino acid sequence of mouse VLCS, and Dr. Hugo Moser for helpful discussions.

    FOOTNOTES

* This work was supported by National Institutes of Health Grants HD10981, HD24061, and NS10533.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§ To whom correspondence should be addressed: Kennedy Krieger Institute, 707 N. Broadway, Baltimore, MD 21205. Tel.: 410-502-9493; Fax: 410-502-8279; E-mail: watkins{at}kennedykrieger.org.

1 The abbreviations used are: CoA, coenzyme A; VLCFA, very long-chain fatty acid; VLCS, very long-chain acyl-CoA synthetase; rVLCS, rat VLCS; mFATP, mouse fatty acid transport protein; LCS, long-chain acyl-CoA synthetase; FAT1 and Fat1p, S. cerevisiae fatty acid transporter/VLCS gene and protein, respectively; FAA and Faap, S. cerevisiae fatty acid activation gene and protein, respectively; XALD, X-linked adrenoleukodystrophy; ALDP, adrenoleukodystrophy protein; PCR, polymerase chain reaction; bp, base pair(s); kb, kilobase pair(s); MES, 4-morpholineethanesulfonic acid.

2 P. A. Watkins, unpublished observations.

3 N. Shani, J.-F. Lu, and D. Valle, submitted for publication.

4 S. J. Steinberg and P. A. Watkins, submitted for publication.

    REFERENCES
Top
Abstract
Introduction
Procedures
Results
Discussion
References

  1. Watkins, P. A. (1997) Prog. Lipid Res. 36, 55-83[CrossRef][Medline] [Order article via Infotrieve]
  2. Singh, H., and Poulos, A. (1988) Arch. Biochem. Biophys. 266, 486-495[Medline] [Order article via Infotrieve]
  3. Lazo, O., Contreras, M., Hashmi, M., Stanley, W., Irazu, C., and Singh, I. (1988) Proc. Natl. Acad. Sci. U. S. A. 85, 7647-7651[Abstract]
  4. Kalish, J. E., Chen, C. I., Gould, S. J., and Watkins, P. A. (1995) Biochem. Biophys. Res. Commun. 206, 335-340[CrossRef][Medline] [Order article via Infotrieve]
  5. Moser, H. W., Smith, K. D., and Moser, A. B. (1995) in The Metabolic and Molecular Bases of Inherited Disease (Scriver, C. R., Beaudet, A. L., Sly, W. S., and Valle, D., eds), pp. 2325-2349, McGraw-Hill Inc., New York
  6. Wanders, R. J. A., van Roermund, C. W. T., van Wijland, M. J. A., Schutgens, R. B. H., van den Bosch, H., Schram, A. W., and Tager, J. M. (1988) Biochem. Biophys. Res. Commun. 153, 618-624[Medline] [Order article via Infotrieve]
  7. Mosser, J., Douar, A. M., Sarde, C. O., Kioschis, P., Feil, R., Moser, H., Poustka, A. M., Mandel, J. L., and Aubourg, P. (1993) Nature 361, 726-730[CrossRef][Medline] [Order article via Infotrieve]
  8. Kok, F., Neumann, S., Sarde, C. O., Zheng, S., Wu, K. H., Wei, H. M., Bergin, J., Watkins, P. A., Gould, S. J., Moser, H. W., Mandel, J. L., and Smith, K. D. (1995) Hum. Mutat. 6, 104-115[Medline] [Order article via Infotrieve]
  9. Braiterman, L. T., Zheng, S., Watkins, P. A., Geraghty, M. T., Johnson, G., McGuinness, M. C., Moser, A. B., and Smith, K. D. (1998) Hum. Mol. Genet. 7, 239-247[Abstract/Free Full Text]
  10. Cartier, N., Lopez, J., Moullier, P., Rocchiccioli, F., Rolland, M. O., Jorge, P., Mosser, J., Mandel, J. L., Bougneres, P. F., Danos, O., and Aubourg, P. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 1674-1678[Abstract]
  11. Shimozawa, N., Tsukamoto, T., Suzuki, Y., Orii, T., Shirayoshi, Y., Mori, T., and Fujiki, Y. (1992) Science 255, 1132-1134[Medline] [Order article via Infotrieve]
  12. Dodt, G., Braverman, N., Wong, C., Moser, A., Moser, H. W., Watkins, P., Valle, D., and Gould, S. J. (1995) Nat. Genet. 9, 115-125[Medline] [Order article via Infotrieve]
  13. Yahraus, T., Braverman, N., Dodt, G., Kalish, J. E., Morrell, J. C., Moser, H. W., Valle, D., and Gould, S. J. (1996) EMBO J. 15, 2914-2923[Abstract]
  14. Braverman, N., Steel, G., Obie, C., Moser, A., Moser, H., Gould, S. J., and Valle, D. (1997) Nat. Genet. 15, 369-376[Medline] [Order article via Infotrieve]
  15. Chang, C. C., Lee, W. H., Moser, H., Valle, D., and Gould, S. J. (1997) Nat. Genet. 15, 385-388[Medline] [Order article via Infotrieve]
  16. Reuber, B. E., Germain-Lee, E., Morrell, J. C., Geisbrecht, B., Collins, C., Ameritunga, R., Moser, H. W., Valle, D., and Gould, S. J. (1997) Am. J. Hum Genet. 61, (suppl.) A54
  17. Knoll, L. J., Johnson, D. R., and Gordon, J. I. (1994) J. Biol. Chem. 269, 16348-16356[Abstract/Free Full Text]
  18. Johnson, D. R., Knoll, L. J., Levin, D. E., and Gordon, J. I. (1994) J. Cell Biol. 127, 751-762[Abstract]
  19. Uchida, Y., Kondo, N., Orii, T., and Hashimoto, T. (1996) J. Biochem. (Tokyo) 119, 565-571[Abstract]
  20. Uchiyama, A., Aoyama, T., Kamijo, K., Uchida, Y., Kondo, M., Orii, T., and Hashimoto, T. (1996) J. Biol. Chem. 271, 30360-30365[Abstract/Free Full Text]
  21. Schaffer, J. E., and Lodish, H. F. (1994) Cell 79, 427-436[Medline] [Order article via Infotrieve]
  22. Faergeman, N. J., DiRusso, C. C., Elberger, A., Knudsen, J., and Black, P. N. (1997) J. Biol. Chem. 272, 8531-8538[Abstract/Free Full Text]
  23. Altschul, S. F., Gish, W., Miller, W., Myers, E. W., and Lipman, D. J. (1990) J. Mol. Biol. 215, 403-410[CrossRef][Medline] [Order article via Infotrieve]
  24. Brachmann, C. B., Davies, A., Cost, G. J., Caputo, E., Li, J., Hieter, P., and Boeke, J. D. (1998) Yeast 14, 115-132[CrossRef][Medline] [Order article via Infotrieve]
  25. Crane, D. I., Kalish, J. E., and Gould, S. J. (1994) J. Biol. Chem. 269, 21835-21844[Abstract/Free Full Text]
  26. Sherman, F., Fink, G. R., and Hicks, J. B. (1979) Methods in Yeast Genetics, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York
  27. Sikorski, R. S., and Hieter, P. (1989) Genetics 122, 19-27[Abstract/Free Full Text]
  28. Elgersma, Y., Vos, A., van den Berg, M., van Roermund, C. W., van der Sluijs, P., Distel, B., and Tabak, H. F. (1996) J. Biol. Chem. 271, 26375-26382[Abstract/Free Full Text]
  29. Lorenz, M. C., Muir, R. S., Lim, E., McElver, J., and Weber, S. C. (1995) Gene (Amst.) 158, 113-117[CrossRef][Medline] [Order article via Infotrieve]
  30. Erdmann, R., and Blobel, G. (1995) J. Cell Biol. 128, 509-523[Abstract]
  31. Singh, I., Pahan, K., Dhaunsi, G. S., Lazo, O., and Ozand, P. (1993) J. Biol. Chem. 268, 9972-9979[Abstract/Free Full Text]
  32. Watkins, P. A., Ferrell, E. V., Jr., Pedersen, J. I., and Hoefler, G. (1991) Arch. Biochem. Biophys. 289, 329-336[Medline] [Order article via Infotrieve]
  33. Dole, V. P. (1956) J. Clin. Invest. 35, 150-154
  34. Lowry, O. H., Rosebrough, N. J., Farr, A. L., and Randall, R. J. (1951) J. Biol. Chem. 193, 265-275[Free Full Text]
  35. Miller, G. L. (1959) Anal. Chem. 31, 964
  36. Folch, J., Lees, M., and Sloane-Stanley, G. H. (1957) J. Biol. Chem. 226, 457-509
  37. Moser, H. W., and Moser, A. B. (1991) in Techniques in Diagnostic Human Biochemical Genetics (Hommes, F. A., ed), pp. 177-191, Wiley-Liss, New York
  38. Gould, S. J., Keller, G. A., Schneider, M., Howell, S. H., Garrard, L. J., Goodman, J. M., Distel, B., Tabak, H., and Subramani, S. (1990) EMBO J. 9, 85-90[Abstract]
  39. Knoll, L. J., Johnson, D. R., and Gordon, J. I. (1995) J. Biol. Chem. 270, 10861-10867[Abstract/Free Full Text]
  40. Einerhand, A. W. C., Kos, W. T., Distel, B., and Tabak, H. F. (1993) Eur. J. Biochem. 214, 323-331[Abstract]
  41. Wang, T., Luo, Y., and Small, G. M. (1994) J. Biol. Chem. 269, 24480-24485[Abstract/Free Full Text]
  42. Ho, J. K., Moser, H., Kishimoto, Y., and Hamilton, J. A. (1995) J. Clin. Invest. 96, 1455-1463[Medline] [Order article via Infotrieve]
  43. Knazek, R. A., Rizzo, W. B., Schulman, J. D., and Dave, J. R. (1983) J. Clin. Invest. 72, 245-248[Medline] [Order article via Infotrieve]
  44. Whitcomb, R. W., Linehan, W. M., and Knazek, R. A. (1988) J. Clin. Invest. 81, 185-188[Medline] [Order article via Infotrieve]
  45. Hettema, E. H., van Roermund, C. W. T., Distel, B., van den Berg, M., Vilela, C., Rodrigues-Pousada, C., Wanders, R. J. A., and Tabak, H. F. (1996) EMBO J. 15, 3813-3822[Abstract]
  46. Lombard-Platet, G., Savary, S., Sarde, C. O., Mandel, J. L., and Chimini, G. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 1265-1269[Abstract/Free Full Text]
  47. Kamijo, K., Taketani, S., Yokota, S., Osumi, T., and Hashimoto, T. (1990) J. Biol. Chem. 265, 4534-4540[Abstract/Free Full Text]
  48. Shani, N., Steel. G., Dean, M., and Valle, D. (1996) Mol. Biol. Cell 7, (suppl.) 433a
  49. Shani, N., Watkins, P. A., and Valle, D. (1994) Am. J. Hum. Genet. 55, (suppl.) A138
  50. Shani, N., and Valle, D. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 11901-11906[Abstract/Free Full Text]
  51. Dieckmann, R., Lee, Y. O., Vanliempt, H., Vondohren, H., and Kleinkauf, H. (1995) FEBS Lett. 357, 212-216[CrossRef][Medline] [Order article via Infotrieve]
  52. Steinberg, S. J., Kemp, S., Braiterman, L., and Watkins, P. A. (1997) Am. J. Hum. Genet. 61, (suppl.) A262
  53. Black, P. N., Zhang, Q., Weimar, J. D., and DiRusso, C. C. (1997) J. Biol. Chem. 272, 4896-4903[Abstract/Free Full Text]
  54. Watkins, P. A., McGuinness, M. C., Raymond, G. V., Hicks, B. A., Sisk, J. M., Moser, A. B., and Moser, H. W. (1995) Ann. Neurol. 38, 472-477[Medline] [Order article via Infotrieve]
  55. Suzuki, H., Kawarabayasi, Y., Kondo, J., Abe, T., Nishikawa, K., Kimura, S., Hashimoto, T., and Yamamoto, T. (1990) J. Biol. Chem. 265, 8681-8685[Abstract/Free Full Text]
  56. Fujino, T., and Yamamoto, T. (1992) J. Biochem. (Tokyo) 111, 197-203[Abstract]
  57. Fujino, T., Kang, M.-J., Suzuki, H., Iijima, H., and Yamamoto, T. (1996) J. Biol. Chem. 271, 16748-16752[Abstract/Free Full Text]
  58. Abe, T., Fujino, T., Fukuyama, R., Minoshima, S., Shimizu, N., Toh, H., Suzuki, H., and Yamamoto, T. (1992) J. Biochem. (Tokyo) 111, 123-128[Abstract]


Copyright © 1998 by The American Society for Biochemistry and Molecular Biology, Inc.